Sean Michael Smith - 02 Mar 2022 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)

Role
Principal Accounting Officer
Signature
/s/ Sean M. Smith
Issuer symbol
NGNE
Transactions as of
02 Mar 2022
Net transactions value
$0
Form type
4
Filing time
03 Mar 2022, 15:39:51 UTC
Next filing
04 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Stock Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 02 Mar 2022 Common Stock 80,000 $2.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the option will vest on March 2, 2023, and 1/48 of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.